

SPARK - A CME Course on Lewy Body Dementia 2021 – ONLINE

Activity Description

Lewy body dementia (LBD) is a brain disease involving two related clinical disorders: dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). DLB is the second most common form of degenerative dementia in the elderly next to Alzheimer's disease (AD).

This half day virtual CME course is intended to educate health care providers on detection, diagnosis, treatment and care management of Lewy Body Dementia (LBD) and to educate healthcare providers on best practices around diagnosis disclosure and become familiar with important referrals that help patients and families address the daily difficulties associated with LBD.

The program includes a combination of immersive learning through lectures, film experience, and panel discussions.

Target Audience

This course is targeted to primary care physicians, specialty physicians, nurses, nurse practitioners, physician assistants, psychologists, neuropsychologists, social workers, occupational therapists, and physical therapist. This course may also be of interest to physicians who practice in family medicine, geriatrics, hospice and palliative medicine, internal medicine, lifestyle and mind-body medicine, medical genetics and genomics, palliative Medicine, physical medicine & rehab, preventative medicine, psychiatry and neurology, psychology and mental health.

Learning Objectives

Upon conclusion of this activity, participants should be able to:

- Explain the neuropathology underlying DLB and how the distribution of pathology correlates with symptom presentation
- Define diagnostic criteria of LBD
- Describe specific reasons why a timely diagnosis is valuable to person with LBD and their families
- Outline the principles of LBD care and medical management
- Outline 'best practices' when disclosing a diagnosis
- Become familiar with LBD resources to recommend and refer families to including local LBD programs and the LBDA

Attendance at this Mayo Clinic course does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course.

Accreditation Statement



In support of improving patient care, this activity is planned and implemented by Mayo Clinic College of Medicine and Science and Lewy Body Dementia Association (LBDA). Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statements

AMA

Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC

Mayo Clinic College of Medicine and Science designates this activity for a maximum of 3.25 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Other Healthcare Professionals

A record of attendance will be provided to all registrants for requesting credits in accordance with state nursing boards, specialty societies or other professional associations.

Disclosure Summary

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program who have disclosed...

Relevant financial relationships with industry:

Name	Nature of Relationship	Company
Bradley F. Boeve, M.D.	Investigator	Clinical trials sponsored by EIP Pharma

No relevant financial relationship(s) with industry:

Leah K. Forsberg, Ph.D., M.S.	Mr. Joshua W. Ohde
Ms. Miriam Giles	Ms. Julie Reed
Jonathan Graff-Radford, M.D.	Rodolfo Savica, M.D., Ph.D.
Mr. Todd C. Graham	Ms. Susan Schneider Williams
Angela M. Lunde, M.A.	Ms. Angela Taylor
Jodi L. Melius, R.N.	Ericka E. Tung, M.D., M.P.H.

References to off-label and/or investigational usage(s) of pharmaceuticals or instruments in their presentation:

Name	Manufacturer/Provider	Product/Device
Bradley F. Boeve, M.D.	Dr. Boeve may discuss use of several medications that are not FDA-approved for the indications that are reviewed, which may include the use of melatonin, clonazepam, cholinesterase inhibitors, carbidopa/levodopa, dopamine agonists, selective serotonin reuptake inhibitors, atypical neuroleptics/antipsychotics, amyloid immunotherapies, putative tau-active agents, α -synuclein-active agents, memantine, sedative/hypnotics, and psychostimulants for the management of cognitive impairment, neuropsychiatric disorders, parkinsonism, sleep disorders, and autonomic dysfunction. Neuroimaging	

modalities involving PET and SPECT ligands which are not FDA-approved for the indications that are reviewed will also be discussed.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) please visit: <https://ce.mayo.edu/content/disclosures>.

Disclaimer

Participation in this Mayo Clinic educational activity does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course. You should be aware that substantive developments in the medical field covered by this recording may have occurred since the date of original release.

Prerequisites for Participation

There are no prerequisites needed prior to participating in this education activity.

Method of Participation

Participation in this activity consists of reviewing the educational material, completing the learner assessment and evaluation.

How to Obtain Credit

To obtain credit, review the course materials, complete the assessment, evaluation, and submit.

Release and Expiration Dates

Release Date: February 24, 2021
Expiration Date: December 31, 2022

Acknowledgement of Commercial Support

No commercial support was received in the production of this activity.

Faculty and Course Director Listing and Credentials

Course Directors

Bradley F. Boeve, M.D.
Ms. Angela M. Lunde, M.A.

Guest Faculty

Mr. Todd C. Graham, Lewy Body Dementia Association
Ms. Susan Schneider Williams

Mayo Clinic Faculty

Jonathan Graff-Radford, M.D.
Mr. Joshua W. Ohde
Rodolfo Savica, M.D., Ph.D.
Ericka E. Tung, M.D., M.P.H.

Planning Committee Members

Leah K. Forsberg, Ph.D., M.S., Mayo Clinic
Ms. Miriam Giles, Lewy Body Dementia Association
Jodi L. Melius, R.N., Mayo Clinic
Ms. Angela Taylor, Lewy Body Dementia Association

Bibliographic Resources

McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology*. 2017 Jul 4;89(1):88-100. doi: 10.1212/WNL.0000000000004058. Epub 2017 Jun 7. PMID: 28592453

Taylor JP, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, Allan LM, Thomas AJ, O'Brien JT. New evidence on the management of Lewy body dementia. *Lancet Neurol*. 2020 Feb;19(2):157-169. doi: 10.1016/S1474-4422(19)30153-X. Epub 2019 Sep 10. PMID: 31519472

(Galvin, J. E., Duda, J. E., Kaufer, D. I., Lippa, C. F., Taylor, A., & Zarit, S. H. (2010). Lewy body dementia: the caregiver experience of clinical care. *Parkinsonism & related disorders*, 16(6), 388–392.

Copyright

Mayo Foundation for Medical Education and Research. All rights reserved. Copyright 2021